Egfr and eml4-alk updated therapies in non-small cell lung cancer

Date
2016Author
de Mello, Ramon Andrade
Liu, Davi J. J. [UNIFESP]
Aguiar, Pedro N., Jr. [UNIFESP]
Tadokoro, Hakaru [UNIFESP]
Type
RevisãoISSN
1574-8928Is part of
Recent Patents On Anti-Cancer Drug DiscoveryDOI
10.2174/1574892811666160803090944Metadata
Show full item recordAbstract
Background: Non-small cell lung cancer is the leading cancer-related cause of death. Objective: We review the latest therapies for NSCLC with EGFR and ELM4-ALK mutations as well as the most relevant studies and promising patents. Method: A literature search of PubMed database was carried out to identify recent Clinical Trials using EGFR therapies and novel patents involving diagnosis and therapies on NSCLC. We conducted a search to find new therapy strategies, new biomarkers, and selected five patents we find relevant. Results: Over the last few years, identification of cancer harboring epidermal growth factor receptor mutations (EGFR) or chromosomal rearrangements of anaplastic lymphoma kinase (ALK) led to new ways in classifying and treating NSCLC. On the other hand, acquired resistance are a constantly challenge in the management of patients with these mutations and new drugs options are in development to improve and amplify treatment strategies. Conclusions: Currently, EGFR TKIs (e. g.: erlotinib, gefitinib, osimertinib) and ALK inhibitors (crizotinib, ceritinib, alectinib) provided a new face for advanced NSCLC outcomes. To understand the disease molecular profile is mandatory to define the best approach for each patient.
Citation
Recent Patents On Anti-Cancer Drug Discovery. Sharjah, v. 11, n. 4, p. 393-400, 2016.Keywords
AfatinibEgfr
Elm4-Alk
Erlotinib
Geftinib
Non-Small Cell Lung Cancer
Osimertinib
PatentTyrosine Kinase Inhibitors
T790m Mutation
1st-Line Treatment
Open-Label
Phase-Iii
Chemotherapy
Gefitinib
Erlotinib
Trial
Crizotinib
Collections
- EPM - Artigos [17701]